Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria:
• * No radiographic evidence of disease
• * Stable disease, defined as no tumor progression within the past 3 months
• Previously treated with 1 course of localized or whole brain radiotherapy of at least 3,000 cGy at least 6 months before study registration
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 70-100%
• Life expectancy
• At least 30 weeks
• Hematopoietic
• Not specified
• Hepatic
• Not specified
• Renal
• Not specified
• Other
• Not pregnant or nursing
• Negative pregnancy test
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No concurrent chemotherapy
• Endocrine therapy
• Concurrent steroid therapy allowed if on stable or decreasing dose
• Radiotherapy
• See Disease Characteristics
• No concurrent cranial radiotherapy
• Surgery
• No concurrent surgery
• Other
• More than 3 months since prior donepezil or EGb761
• No concurrent donepezil (group 2 only)
• No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)
• No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or enoxaparin) (group 2 only)
• No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)
• No other concurrent therapy